Project Grant R61AG088966
Award Date
8/15/24
Completion Date
7/31/25
Dollars Obligated
$297K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) aims to advance health equity in the use of novel treatments for Alzheimer's disease and related dementias (ADRD). The $322,286 award to The Johns Hopkins University will fund a two-phase project. In the planning phase (R61), the researchers will conduct focus groups to understand medication decision-making processes of diverse individuals affected by ADRD. They will then design discrete choice experiments...
The National Institute on Aging (NIA) awarded a $331,439 Project Grant under the Aging Research program (CFDA 93.866) to the Regents of the University of Michigan. This 1-year project, titled "Health Equity in Alzheimer's Treatment (HEAT)", aims to better understand the effectiveness and cost-effectiveness of new anti-amyloid medications for treating Alzheimer's disease in Black and low-income populations. The key activities include: 1) using a mixed-methods approach to assess...
This $334,788 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the impact of recent revisions to the Medicare home health payment system (Patient-Driven Groupings Model or PDGM) on access, care delivery, and outcomes for community-living Medicare beneficiaries with Alzheimer's disease and related dementias (ADRD). The 2-year study, starting September 1, 2023, will leverage Medicare claims, home health assessment, and agency data to:...
This $424,184 Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 (Aging Research) aims to study racial and ethnic disparities in access to Alzheimer's Special Care Units (SCUs) in nursing homes, and how disparities in SCU access may contribute to disparities in health outcomes for Black and Hispanic residents with Alzheimer's disease and related dementias (ADRD). The study will analyze national Medicare claims and nursing home assessment data from 2011-2019 to...
The federal Project Grant award R61AG089049, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to assess cost and non-cost barriers to the use of novel Alzheimer's disease (AD) and related dementia (ADRD) therapeutics among older Hispanic or Latino adults. The project will involve semi-structured interviews with a cohort of Latino adults and Latino patients with AD/ADRD and their caregivers, followed by a population-based survey to systematically capture the...
This federal Project Grant award, funded by the National Institute on Aging (CFDA 93.866 Aging Research), supports a 5-year, $1,550,462 cross-sectional, longitudinal, and observational study to investigate the impact of Alzheimer's disease (AD) risk genes, with a focus on APOE E4, on brain function in older Black/African American adults living with HIV. The study aims to address the significant public health challenge of the potential "double-hit" of HIV-associated neurocognitive...
This $3,281,385 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) aims to leverage 30 years of Alzheimer's disease clinical trials data to examine how specific patient phenotypes, such as sex/gender, APOE4 status, and polygenic hazard scores, influence responses to drug and lifestyle interventions. The research will analyze data from 14,602 participants across multiple harmonized Alzheimer's clinical trials datasets, utilizing advanced statistical models...
This federal Project Grant award of $1,846,173 from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research to understand the impact of Medicare Advantage (MA) coverage on healthcare utilization and intergenerational transfers among patients with Alzheimer's disease and related dementias (ADRD). The 5-year project, running from August 2024 to April 2029, will examine differences in potentially preventable hospitalizations, burdensome transfers, and post-discharge...
This $1,588,040 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support a study examining the role of home-based medical care (HBMC) and telemedicine in the care and outcomes of individuals with Alzheimer's disease and related dementias (ADRD) who have Medicare coverage, either through the public fee-for-service program or private Medicare Advantage plans. The study aims to identify national trends in HBMC and telemedicine use, and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $778,551 to The Rand Corporation to conduct research on disparities in undiagnosed and misdiagnosed dementia, including Alzheimer's disease and related dementias (AD/ADRD), and the impact on healthcare utilization and costs. The key objectives are to: 1) Develop a novel probabilistic method to classify AD/ADRD status among over 10 million Medicare beneficiaries, 2) Estimate the impact of...